Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial

IMPORTANCE: Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus disease 2019 (COVID-19). OBJECTIVE: To determine whether tocilizumab (TCZ) improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia. DESIGN, SETTING, AN...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Intern Med
Hlavní autoři: Hermine, Olivier, Mariette, Xavier, Tharaux, Pierre-Louis, Resche-Rigon, Matthieu, Porcher, Raphaël, Ravaud, Philippe
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2020
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7577198/
https://ncbi.nlm.nih.gov/pubmed/33080017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2020.6820
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky